Perspective Therapeutics (CATX) Deferred Taxes (2023 - 2024)
Perspective Therapeutics (CATX) reported Deferred Taxes of -$2.1 million for Q4 2024, down 126.72% on a YoY basis from $7.8 million in Q1 2024, and down 126.72% sequentially from $7.8 million in Q4 2023.
Perspective Therapeutics (CATX) Deferred Taxes (2023 - 2024) Analysis & Trends
Perspective Therapeutics (CATX) has 2 years of Deferred Taxes data on file, last reported at -$2.1 million in Q4 2024.
- For the quarter ending Q4 2024, Deferred Taxes fell 126.72% year-over-year to -$2.1 million; the trailing twelve-month figure through Dec 2024 stood at -$2.1 million (up 20.9% YoY), and the FY2024 full-year result was -$2.1 million, up 20.9% from the prior year.
- Deferred Taxes eased to -$2.1 million in Q4 2024, from $7.8 million in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $7.8 million in Q4 2023 to a low of -$10.5 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -33.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -8.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -351.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -9.40 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 7.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 51.51 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Perspective Therapeutics | 146.05 Mn | 146.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.10 Mn |
| Dec 31, 2023 | 7.85 Mn |
| Mar 31, 2023 | -10.50 Mn |